Health-related utility among adults with atopic dermatitis treated with 0·1% tacrolimus ointment as maintenance therapy over the long term: Findings from the Protopic® CONTROL study

British Journal of Dermatology

Volumn 161, Issue 6, 2009, Pages 1335-1340

  Poole, C D ^a   Chambers, C ^b   Sidhu, M K ^b   Currie, C J ^c  

^a Pharmatelligence   (United Kingdom)

^b ASTELLAS PHARMA EUROPE LTD   (United Kingdom)

^c CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

Atopic dermatitis; Quality of life; Tacrolimus

Indexed keywords

EMOLLIENT AGENT; TACROLIMUS;

ADULT; ALGORITHM; ARTICLE; ATOPIC DERMATITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; LONG TERM CARE; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MONTE CARLO METHOD; MULTICENTER STUDY; OINTMENT; OPEN STUDY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SHORT FORM 12; TREATMENT DURATION; UNITED KINGDOM;

ADULT; DERMATITIS, ATOPIC; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; OINTMENTS; QUALITY OF LIFE; TACROLIMUS; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 72649099100     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2009.09379.x     Document Type: Article

References (31)

1. Hanifin JM, Rajka G. Diagnostic features of atopic dermatitis. Acta Derm Venereol (Stockh) 1980 92 (Suppl. 44 7.
2. Williams HC, Strachan DP. The natural history of childhood eczema: observations from the British 1958 birth cohort study. Br J Dermatol 2003 139 : 834 839.
3. Gupta R, Sheikh A, Strachan DP, Anderson HR. Time trends in allergic disorders in the UK. Thorax 2007 62 : 91 6.
4. Dolan P. Modelling valuations for EuroQol health states. Med Care 1997 35 : 1095 1108.
5. Torrance GW, Furlong W, Feeny D, Boyle M. Multi-attribute preference functions. Health Utilities Index. Pharmacoeconomics 1995 7 : 503 520.
6. Lewis V, Finlay AY. 10 years experience of the Dermatology Life Quality Index (DLQI). J Investig Dermatol Symp Proc 2004 9 : 169 180.
7. Su JC, Kemp AS, Varigos GA, Nolan TM. Atopic eczema: its impact on the family and financial cost. Arch Dis Child 1997 76 : 159 162.
8. NICE technology appraisal guidance 103. Etanercept and Efalizumab for the Treatment of Adults with Psoriasis. London : National Institute for Health and Clinical Excellence, 2006.
9. National Institute for Health and Clinical Excellence. Guide to the Methods of Technology Appraisal (Reference N0515), 2004. Available at http://www.nice.org.uk/download.aspx?o=201973 [last accessed 12 July 2009].
10. Pitt M, Garside R, Stein K. A cost-utility analysis of pimecrolimus vs. topical corticosteroids and emollients for the treatment of mild and moderate atopic eczema. Br J Dermatol 2006 154 : 1137 1146.
11. Stevens KJ, Brazier JE, McKenna SP et al. The development of a preference-based measure of health in children with atopic dermatitis. Br J Dermatol 2005 153 : 372 377.
12. The PenTAG Value of Health Panel. Available at http://www.valueofhealth. org/background.php [last accessed 13 December 2006].
13. Brazier J, Deverill M, Green C et al. A review of the use of health status measures in economic evaluation. Health Technol Assess 1999 3 : 1 164.
14. Gray AM, Rivero-Arias O, Clarke PM. Estimating the association between SF-12 responses and EQ-5D utility values by response mapping. Med Decis Making 2006 26 : 18 29.
15. Reitamo S, Ortonne J-P, Sand C et al. Long-term treatment with 0.1% tacrolimus ointment in adults with atopic dermatitis: results of a two-year, multicentre, noncomparative study. Acta Derm Venereol 2007 87 : 406 412.
16. Wollenberg A, Reitamo S, Girolomoni G et al. Proactive treatment of atopic dermatitis in adults with 0.1% tacrolimus ointment. Allergy 2008 63 : 742 750.
17. Rajka G, Langeland T. Grading of the severity of atopic dermatitis. Acta Derm Venereol (Stockh) 1989 144 (Suppl. 13 14.
18. Hanifin JM. EASI Correlates with IGA and Validates its Use as a Measure of Atopic Eczema. Presented at 61st Annual Meeting of the American Academy of Dermatology, 21-26 March 2003, San Francisco, CA, U.S.A., abstract P210.
19. Jenkinson C, Stewart-Brown S, Petersen S, Paice C. Assessment of the SF-36 version 2 in the United Kingdom. J Epidemiol Community Health 1999 53 : 46 50.
20. Brazier J, Roberts J, Deverill M. The estimation of a preference-based measure of health from the SF-36. J Health Econ 2002 21 : 271 292.
21. Brazier JE, Roberts J. The estimation of a preference-based measure of health from the SF-12. Med Care 2004 42 : 851 859.
22. SF-36. Available at http://www.sf-36.org/tools/sf12.shtml [last accessed 27 July 2009].
23. Woolacott N, Hawkins N, Mason A et al. Etanercept and efalizumab for the treatment of psoriasis: a systematic review. Health Technol Assess 2006 10 : 1 233.
24. Sullivan PW, Lawrence WF, Ghushchyan V. A national catalog of preference-based scores for chronic conditions in the United States. Med Care 2005 43 : 736 749.
25. Walters SJ, Brazier JE. Comparison of the minimally important difference for two health state utility measures: EQ-5D and SF-6D. Qual Life Res 2005 14 : 1523 1532.
26. Walters SJ, Brazier JE. What is the relationship between the minimally important difference and health state utility values? The case of the SF-6D Health Qual Life Outcomes 2003 1 : 4.
27. Sullivan PW, Ghushchyan V. Preference-based EQ-5D index scores for chronic conditions in the United States. Med Decis Making 2006 26 : 410 420.
28. Thaçi D, Reitamo S, Gonzalez Ensenat MA et al. Proactive disease management with 0.03% tacrolimus ointment for children with atopic dermatitis: results of a randomized, multicentre, comparative study. Br J Dermatol 2008 159 : 1348 1356.
29. Kang S, Lucky AW, Pariser D et al., for the Tacrolimus Ointment Study Group. Long-term safety and efficacy of tacrolimus ointment for the treatment of atopic dermatitis in children. J Am Acad Dermatol 2001 44 (Suppl. S58 64.
30. Reitamo S, Harper J, Bos JD et al. 0.03% tacrolimus ointment applied once or twice daily is more is efficacious than 1% hydrocortisone acetate in children with moderate to severe atopic dermatitis: results of a randomized double-blind controlled trial. Br J Dermatol 2004 150 : 554 562.
31. Wollenberg A, Sidhu MK, Odeyemi I et al. Economic evaluation of maintenance treatment with tacrolimus 0.1% ointment in adults with moderate to severe atopic dermatitis. Br J Dermatol 2008 159 : 1322 1330.